<DOC>
	<DOCNO>NCT02250209</DOCNO>
	<brief_summary>The objective study assess clinical efficacy safety trastuzumab plus XELOX treatment HER2-positive Stage III Gastric Cancer After D2 Gastrectomy .</brief_summary>
	<brief_title>T- XELOX HER2-positive Stage III Gastric Cancer After D2 Gastrectomy</brief_title>
	<detailed_description>Gastric cancer second lead cause cancer death worldwide . Highest incidence rate observe Eastern Asia . D2 gastrectomy establish standard surgical procedure . While recurrence rate resection still high . The CLASSIC study show Xelox regimen D2 gastrectomy improve 3-year disease-free survival compare surgery . But patient late stage still poor prognosis accord subgroup analysis retrospective study . HER2 important biomarker key driver tumorigenesis 7-34 % gastric cancer . The ToGA study show trastuzumab , monoclonal antibody target HER2 , plus chemotherapy improve overall survival ( 16.0m vs 11.8m ) patient HER2-positive advanced gastric gastro-oesophageal junction cancer . Based previous experience trastuzumab adjunctive therapy breast cancer ACTS/CLASSIC/ToGA study , suppose trastuzumab plus XELOX adjunctive treatment may benefit patient HER2-positive Stage III gastric cancer D2 Gastrectomy . According , single-arm research ass clinical efficacy safety trastuzumab plus XELOX treatment HER2-positive Stage III Gastric Cancer After D2 Gastrectomy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Signed informedconsent form . 2 . Aged 1880 year . 3 . Had partial total D2 gastrectomy achieve R0 resection . 4 . Histologically confirm gastric gastrooesophageal junction adenocarcinoma，mucinous adenocarcinoma ，signetring cell carcinoma 5 . Pathologic Stage III ( IIIAC ) . 6 . HER2positive : ( IHC 3+ IHC 2+ FISH positive ) . 7 . Patients must receive preoperative chemotherapy radiation therapy . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 9 . Adequate liver/bone marrow function.Blood biochemical parameter ; 10 . Compliant , follow regularly . 1 . Patients meet Inclusion Criteria . 2 . Pregnant breastfeed female , willing take contraception measure study . 3 . Serious infection require antibiotic intervention recruitment . 4 . Allergic study drug metabolism disorder . 5 . Histologically confirm small cell carcinoma stomach、gastric neuroendocrine carcinoma others . 6 . Uncontrolled brain metastasis mental illness . 7 . Organ transplant recipient ( Autologous transplantation bone marrow peripheral stem cell transplantation include ) . 8 . Congestive heart failure , uncontrolled cardiac arrhythmia , etc . 9 . With severe hepatic/kidney/respirator/disease , chronic disease like uncontrolled diabetes , hypertension , etc . 10. malignant tumor . 11 . Can follow obey protocol . 12 . Ineligible discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>XELOX</keyword>
	<keyword>Stage III</keyword>
	<keyword>D2 Gastrectomy</keyword>
</DOC>